XOMA Royalty
XOMA
Performance
About XOMA Royalty
XOMA Royalty operates as a biotech royalty aggregator, acquiring the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates. The company provides non-dilutive, non-recourse funding to selling biotech firms to advance their internal drug candidates. With a portfolio of 120+ assets, XOMA Royalty focuses on monetizing royalties and milestone streams from licensed assets developed by others, enabling funding for continued development. The organization positions itself at the intersection of biotech innovation and capital efficiency, serving the pharmaceutical and biotech sectors globally.
Recent News
The BioPharm Brief: Survodutide Data, Orca-Q RMAT, Ligand Deal
Fed Rate Cut Tailwind, Lilly’s Triple Agonist Delivers Big, Vaccine Policy Turmoil — This Week in Biotech #81
XOMA Royalty: Preferreds Still Offer Compelling Income Despite Call Risk
$739 Million Acquisition of XOMA Strengthens Ligand’s Biopharma Portfolio
Alkermes’ Richard Pops to Step Down After Three-Decade Run as CEO
Ligand Pharmaceuticals Acquires XOMA Royalty in a $739 Million Deal